HR Execs on the Move

Makindus

www.makindus.com

 
Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.makindus.com
  • 3805 Old Easton Road
    Doylestown, PA USA 18902
  • Phone: 267.291.4912

Executives

Name Title Contact Details

Similar Companies

Geneos Therapeutics

Geneos is developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells.

Santen

Santen Inc. is a Napa, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

FASgen

FASgen is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Insilico Medicine

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in the USA, Belgium, Russia, UK, Taiwan, and China sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research. Insilico Medicine pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson`s Disease, Alzheimer`s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief.

Sellas Life Sciences

Sellas Life Sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. In other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. Our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of Σellas. We strive to improve patients` quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.